Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Evaluation of Vitrectomy for Diabetic Macular Edema (Vitrectomy-D)
This study is ongoing, but not recruiting participants.
Sponsored by: National Eye Institute (NEI)
Information provided by: National Eye Institute (NEI)
ClinicalTrials.gov Identifier: NCT00709319
  Purpose

The study is designed as a prospective cohort study to assess changes in visual acuity and retinal thickening and surgical complications in subjects undergoing vitrectomy for diabetic macular edema.

The study also aims to identify subgroups in which there appears to be a benefit of vitrectomy and subgroups in which vitrectomy does not appear to be beneficial and to obtain data that can be used to plan a randomized trial.

Subject will be followed through 2 years, with a primary outcome at 6 months post vitrectomy surgery. The vitrectomy procedure will be performed based on the investigators usual care and is not considered part of the research although the procedure performed will be collected.


Condition
Diabetic Retinopathy
Diabetic Macular Edema

Genetics Home Reference related topics: X-linked juvenile retinoschisis
MedlinePlus related topics: Diabetic Eye Problems Edema Retinal Disorders
U.S. FDA Resources
Study Type: Observational
Study Design: Cohort, Prospective
Official Title: Evaluation of Vitrectomy for Diabetic Macular Edema Study

Further study details as provided by National Eye Institute (NEI):

Primary Outcome Measures:
  • visual acuity [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • OCT central subfield thickness [ Time Frame: 6 Months ] [ Designated as safety issue: No ]
  • surgical complications (including intraoperative and perioperative medical complications) [ Time Frame: Post surgery ] [ Designated as safety issue: Yes ]

Biospecimen Retention:   None Retained

Biospecimen Description:

Enrollment: 241
Study Start Date: July 2005
Estimated Study Completion Date: December 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Groups/Cohorts
Primary
Subjects vitreomacular traction, visual acuity 20/63 to 20/400, retinal thickness >300 microns in the central subfield on OCT, and cataract extraction not being performed in conjunction with vitrectomy.
Secondary
Subjects not meeting criteria for primary cohort

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

adults with diabetic macular edema

Criteria

Subject-level Inclusion Criteria

To be eligible, the following inclusion criteria (1-3) must be met:

  1. Age >= 18 years
  2. Diagnosis of diabetes mellitus (type 1 or type 2)
  3. Able and willing to provide informed consent.

    Subject-level Exclusion Criteria

    A patient is not eligible if any of the following exclusion criteria (4-6) are present:

  4. A condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure and glycemic control).
  5. Patient is expecting to move out of the area of the clinical center to an area not covered by another clinical center during the first year of the study.
  6. Blood pressure >180/110 (systolic above 180 OR diastolic above 110).

Study Eye Criteria

To be a study eye, all of the inclusion criteria (a-e) and none of the exclusion criteria (f-m) listed below must be met. A patient can have only one study eye. If both eyes are eligible and undergoing vitrectomy, the first eye having surgery will be the study eye.

The eligibility criteria for a study eye are as follows:

Inclusion

  1. Vitrectomy being performed as treatment for DME.
  2. E-ETDRS visual acuity 20/800 or better (E-ETDRS visual acuity score >= 3 letters).
  3. Definite retinal thickening due to diabetic macular edema based on clinical exam involving the center of the macula.
  4. Presence of vitreomacular traction associated with macular edema OR edema is felt to be too diffuse to respond to focal or grid laser OR edema judged to be inadequately responsive to previous treatment(s) and unlikely to benefit from further focal photocoagulation.
  5. Media clarity, pupillary dilation, and patient cooperation sufficient for adequate fundus photographs.

    Exclusion

  6. Macular edema is considered to be due to a cause other than diabetic macular edema.
  7. An ocular condition is present such that, in the opinion of the investigator, visual acuity would not improve from resolution of macular edema (e.g., foveal atrophy, pigmentary abnormalities, subfoveal hard exudates, fibrous metaplasia, nonretinal condition).
  8. An ocular condition is present (other than diabetes) that, in the opinion of the investigator, might affect macular edema or alter visual acuity during the course of the study (e.g., vein occlusion, uveitis or other ocular inflammatory disease, neovascular glaucoma, post-surgical cystoid macular edema, etc.).
  9. History of retinal macular photocoagulation, intravitreal corticosteroids, or other treatment for DME within 3.5 months prior to enrollment.
  10. History of peripheral scatter photocoagulation within 4 months prior to enrollment or anticipated need within the 4 months following enrollment.
  11. History of prior pars plana vitrectomy.
  12. History of major ocular surgery (including cataract extraction, scleral buckle, any intraocular surgery, etc.) within prior 6 months or anticipated within the next 6 months following enrollment.
  13. History of YAG capsulotomy performed within 2 months prior to enrollment.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00709319

Sponsors and Collaborators
Investigators
Study Chair: Julia A. Haller, M.D. Wills Eye Institute
  More Information

Diabetic Retinopathy Clinical Research Network  This link exits the ClinicalTrials.gov site
NEI Clinical Studies Database  This link exits the ClinicalTrials.gov site

Responsible Party: Jaeb Center for Health Research ( Roy W. Beck, M.D., Ph.D., Director )
Study ID Numbers: NEI-125
Study First Received: July 1, 2008
Last Updated: July 1, 2008
ClinicalTrials.gov Identifier: NCT00709319  
Health Authority: United States: Federal Government

Keywords provided by National Eye Institute (NEI):
Diabetic retinopathy
Diabetic macular edema
dme
vitrectomy

Study placed in the following topic categories:
Eye Diseases
Vascular Diseases
Diabetes Mellitus
Edema
Endocrine System Diseases
Macular Degeneration
Retinal Degeneration
Diabetic Angiopathies
Macular Edema
Signs and Symptoms
Diabetic Retinopathy
Endocrinopathy
Retinal Diseases
Diabetes Complications
Retinal degeneration

Additional relevant MeSH terms:
Cardiovascular Diseases

ClinicalTrials.gov processed this record on January 14, 2009